At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye. Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society as a whole. Driven by our passion to improve care, we will transform the retinal health landscape by developing novel treatments and technologies, especially where nothing currently exists. Our ambition is clear - prevent vision loss in people at risk and preserve or restore vision in those with retinal diseases. Science and innovation are at the core of the comprehensive pipeline portfolio we have built in Retinal Health, with the first assets already in clinical development.